Hylomorph secures CHF 3.2m Series A round
16.09.2018
Zurich based medtech Hylomorph announced the completion of a CHF 3.2m Series A financing that will allow the company to finalise product development and conduct clinical studies required for FDA approval and the CE-Marking.
1.png) © Tina Sturzenegger
|
 |
The financing round was led by Fongit Seed Invest and included business angels from the Start Angel Network Zurich, Zürcher Kantonalbank and Investiere.
ETH spin-off Hylomorph solves the problem of fibrotic encapsulation encountered by all implantable medical devices. When a foreign material - such as a cardiac arrhythmia device or breast implants - is implanted in a human body, it reacts by encapsulating it in a dense layer of fibrotic connective tissue. Hylomorph has developed a unique biomaterial which interacts with the sensing mechanism of cells thus maintaining the healthy interaction between device and tissue.
The startup has successfully completed all Venture Kick stages in 2016. Simone Bottan, CEO and co-founder of Hylomorph, says: “Venture Kick is a great training program for startuppers. In particular, it showed me the importance of execution in entrepreneurship."
ETH spin-off Hylomorph solves the problem of fibrotic encapsulation encountered by all implantable medical devices. When a foreign material - such as a cardiac arrhythmia device or breast implants - is implanted in a human body, it reacts by encapsulating it in a dense layer of fibrotic connective tissue. Hylomorph has developed a unique biomaterial which interacts with the sensing mechanism of cells thus maintaining the healthy interaction between device and tissue.
The startup has successfully completed all Venture Kick stages in 2016. Simone Bottan, CEO and co-founder of Hylomorph, says: “Venture Kick is a great training program for startuppers. In particular, it showed me the importance of execution in entrepreneurship."